These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9359506)

  • 1. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia.
    van den Heuvel-Eibrink MM; van der Holt B; te Boekhorst PA; Pieters R; Schoester M; Löwenberg B; Sonneveld P
    Br J Haematol; 1997 Oct; 99(1):76-83. PubMed ID: 9359506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
    Lamy T; Goasguen JE; Mordelet E; Grulois I; Dauriac C; Drenou B; Chaperon J; Fauchet R; le Prise PY
    Leukemia; 1994 Nov; 8(11):1879-83. PubMed ID: 7526090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
    Willman CL
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment.
    Hunault M; Zhou D; Delmer A; Ramond S; Viguié F; Cadiou M; Perrot JY; Levy V; Rio B; Cymbalista F; Zittoun R; Marie JP
    Ann Hematol; 1997 Feb; 74(2):65-71. PubMed ID: 9063375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
    Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filí C; Baccarani M; Russo D
    Br J Haematol; 2007 Jan; 136(1):87-95. PubMed ID: 17222198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia.
    Kim DH; Lee NY; Baek JH; Kim JG; Sohn SK; Suh JS; Lee KS; Lee KB
    Leuk Lymphoma; 2006 Mar; 47(3):461-7. PubMed ID: 16396769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia.
    Del Poeta G; Stasi R; Aronica G; Venditti A; Cox MC; Bruno A; Buccisano F; Masi M; Tribalto M; Amadori S; Papa G
    Blood; 1996 Mar; 87(5):1997-2004. PubMed ID: 8634450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-drug resistance (MDR1) gene expression in de novo acute leukemia cells: correlations with CD surface markers and treatment outcome.
    Jiang EZ; Chang YJ; Lee JW; Lee WK; Kim JS; Sohn SK; Lee KB; Suh JS
    J Korean Med Sci; 1998 Dec; 13(6):617-22. PubMed ID: 9886170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.
    Damiani D; Tiribelli M; Raspadori D; Michelutti A; Gozzetti A; Calistri E; Candoni A; Chiarvesio A; Lenoci M; Russo D; Fanin R
    Hematol Oncol; 2007 Mar; 25(1):38-43. PubMed ID: 17200981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy resistance in acute myeloid leukaemia.
    Sonneveld P; List AF
    Best Pract Res Clin Haematol; 2001 Mar; 14(1):211-33. PubMed ID: 11355932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.
    Schaich M; Soucek S; Thiede C; Ehninger G; Illmer T;
    Br J Haematol; 2005 Feb; 128(3):324-32. PubMed ID: 15667534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival.
    Borg AG; Burgess R; Green LM; Scheper RJ; Yin JA
    Br J Haematol; 1998 Dec; 103(4):1083-91. PubMed ID: 9886324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.